Abivax SA ADR Company Profile
NASDAQ: ABVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Abivax SA at a glance
Abivax SA ADR (NASDAQ: ABVX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Paris, France. Abivax SA is led by Mr. Marc M. P. de Garidel M.B.A. and employs about 98 people. The company's shares have traded publicly since 2023.
At a market capitalization of $7.70 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001956827, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Abivax SA do?
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Business description based on the company's public filings.
Company information
- Legal name
- Abivax SA ADR
- Ticker
- NASDAQ: ABVX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Marc M. P. de Garidel M.B.A.
- Employees
- 98
- Headquarters
- 7-11 Boulevard Haussmann, Paris, France
- Phone
- 33 1 53 83 09 63
- Website
- abivax.com
- IPO year
- 2023
- Market cap
- $7.70B
- SEC CIK
- 0001956827
Companies similar to Abivax SA
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs ABVX |
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.13B | vs ABVX |
| ALKSAlkermes plc | 41.45 | -0.49% | $6.95B | vs ABVX |
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs ABVX |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.65 | -3.18% | $6.84B | vs ABVX |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs ABVX |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs ABVX |
| BLTEBelite Bio Inc ADR | 156.08 | +0.30% | $6.29B | vs ABVX |